Jacobs Levy Equity Management
AIM

Jacobs Levy Equity Management’s AIM ImmunoTech AIM Stock Holding History

Jacobs Levy Equity Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10
Closed -$139K – 1150
2013
Q4 		$139K Sell
10
-5
-33% -$60.4K ﹤0.01% 891
2013
Q3 		$189K Sell
15
-2
-12% -$25.2K ﹤0.01% 862
2013
Q2 		$203K Buy
+17
New +$203K ﹤0.01% 889

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OAM
Occidental Asset Management Burlingame, California $844M AUM 20.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Jacobs Levy Equity Management's AIM Position: Q1 2014 in Review

Jacobs Levy Equity Management sold out of AIM ImmunoTech (AIM) in Q1 2014, closing a stake of 10 shares — an estimated $139K sold.

Jacobs Levy Equity Management first reported a position in AIM in Q2 2013 and held it in 3 quarters. The position peaked at $203K in Q2 2013. 16 funds tracked by Wall St. Rank hold AIM as of Q1 2014.

  • Jacobs Levy Equity Management reported no remaining AIM ImmunoTech position as of Q1 2014 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 10 AIM ImmunoTech shares in Q1 2014, an estimated $139K.
  • Jacobs Levy Equity Management first reported a position in AIM ImmunoTech in Q2 2013 and held it in 3 quarters.
  • Jacobs Levy Equity Management's AIM ImmunoTech position peaked at $203K in Q2 2013.
  • 16 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q1 2014.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2014, filed 15 May 2014.